Luis Jodar

Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs

SCHOLARLY PAPERS

6

DOWNLOADS
Rank 30,809

SSRN RANKINGS

Top 30,809

in Total Papers Downloads

3,166

SSRN CITATIONS

4

CROSSREF CITATIONS

0

Scholarly Papers (6)

1.

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 18 Jan 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 2,112 (14,336)

Abstract:

Loading...

omicron, effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, kaiser

2.

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 30 Jun 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 386 (146,759)
Citation 1

Abstract:

Loading...

BA.2, BA.1, omicron, effectiveness, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, Kaiser Permanente, real-world

3.

Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study

Number of pages: 35 Posted: 21 Dec 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 384 (147,599)
Citation 5

Abstract:

Loading...

effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, cohort, delta

4.

Effectiveness of the BNT162b2 XBB.1.5-Adapted Vaccine Against COVID-19 Hospitalization Related to the JN.1 Variant in Europe: A Test-Negative Case-Control Study Using the id.Drive Platform

Number of pages: 37 Posted: 11 Jun 2024
Pfizer, Inc., P95 Pharmacovigilance and Epidemiology Services, Pfizer, Inc., P95 Pharmacovigilance and Epidemiology Services, P95 Pharmacovigilance and Epidemiology Services, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Autonomous University of Barcelona - Hospital Universitari Vall d'Hebron, University Hospital Ulm, P95 Pharmacovigilance and Epidemiology Services, P95 Pharmacovigilance and Epidemiology Services, University Hospital Ulm, University of Genova - Department of Health Sciences, Ziekenhuis Netwerk Antwerpen (ZNA), Centre Hospitalier Universitaire St-Pierre, FISABIO-Public Health, Universitat Autònoma de Barcelona (UAB), Instituto de Salud Carlos III, Goethe University Frankfurt, Freiburg University, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. and P95 Pharmacovigilance and Epidemiology Services
Downloads 217 (265,578)

Abstract:

Loading...

COVID-19, SARS-CoV-2, COVID-19 vaccination, vaccine effectiveness, BNT162b2, XBB adapted vaccine, JN.1

5.

Impact of SARS-CoV-2 Infective Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) on Clinical Outcomes in a Prospective Cohort Study of Hospitalised Adults

Number of pages: 36 Posted: 21 Oct 2022
University of Bristol - Population Health Sciences, University of Bristol - Academic Respiratory Unit, University of Bristol - Academic Respiratory Unit, University of Bristol - Department of Mathematics, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, University Hospitals Bristol NHS Foundation Trust - Clinical Research and Imaging Centre, University of Bristol - Academic Respiratory Unit, University of Bristol - Bristol Vaccine Centre, University of Bristol - Academic Respiratory Unit, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, University of Bristol - Bristol Vaccine Centre, University of Bristol - Department of Population Health Sciences, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer Inc. - Medical and Scientific Affairs, University of Bristol - Bristol Vaccine Centre, University of Bristol - Engineering Mathematics, University of Bristol - Academic Respiratory Unit and Independent
Downloads 45 (760,810)

Abstract:

Loading...

COVID-19, SARS-CoV-2, acute exacerbation of COPD, COPD, airways disease, respiratory infection

6.

The Effect of Pneumococcal Vaccines on Nasopharyngeal Colonisation Following Human Infection Challenge with Serotype 3 and Serotype 6b

Number of pages: 27 Posted: 16 Jul 2024
Liverpool School of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool School of Tropical Medicine, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Liverpool - School of Tropical Medicine, Imperial College London, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool School of Tropical Medicine, University of Wolverhampton, University of Oxford - Oxford Vaccine Group, Liverpool School of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool School of Tropical Medicine, University of Oxford, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer Pharma GmbH, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer Inc. - Medical and Scientific Affairs, Liverpool School of Tropical Medicine - Department of Clinical Sciences, Liverpool School of Tropical Medicine and Independent
Downloads 22 (951,755)

Abstract:

Loading...

Infectious Diseases, Streptococcus pneumoniae, Pneumococcus, PCV13, Pneumococcal Conjugate Vaccine, PPV23, Pneumococcal polysaccharide vaccine, Serotype 3, Pneumococcal Colonisation, Immunity